|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000027242 |
|
Date of registration:
|
03/05/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
the effect of tofacitinib on bone mineral density in patients with rheumatoid arthritis
|
|
Scientific title:
|
the effect of tofacitinib on bone mineral density in patients with rheumatoid arthritis - the effect of tofa on BMD in RA |
|
Date of first enrolment:
|
2016/08/31 |
|
Target sample size:
|
50 |
|
Recruitment status: |
Complete: follow-up continuing |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031208 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Phase IV
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
kensuke kume |
|
Address:
|
higashi kannon 20-16, hiroshima
Japan |
|
Telephone:
|
0822320707 |
|
Email:
|
kumekensuke@live.jp |
|
Affiliation:
|
hiroshima clinic rheumatology |
|
|
Name:
|
kensuke kume |
|
Address:
|
higashi kannon 20-16, hiroshima
Japan |
|
Telephone:
|
0822320707 |
|
Email:
|
kumekensuke@live.jp |
|
Affiliation:
|
hiroshima clinic rheumatology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: patients had received steroids, bisphosphonates, or parathyroid hormone.
Age minimum:
18years-old
Age maximum:
90years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
to determine the effect of tofacitinib on bone
|
|
Intervention(s)
|
|
tofacitinib
|
|
Primary Outcome(s)
|
|
the comparison of the BMD of the lumbar spine and femoral neck at baseline and 52 weeks after tofacitinib treatment.
|
|
Secondary Outcome(s)
|
|
the comparison of the bone marker at baseline and 52 weeks after tofacitinib treatment
|
|
Source(s) of Monetary Support
|
|
none
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|